Page 210 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 7
Supplementary table 1. Toxicity of study patients compared to patients from literature
Selected studies from literature had relatively large patient cohorts and reported toxicity extensively.
Type of event
Grade 2 Diarrhoea Grade ≥3 Diarrhoea
Grade 2 Nauseab Grade ≥3 Nauseab
Grade 2 Mucositis Grade ≥3 Mucositis
Grade 2 Radiation dermatitisb Grade ≥3 Radiation dermatitisb
Grade 2 Fatiguec Grade ≥3 Fatiguec
Grade 2 HFS Grade 3 HFS
Grade 2 Neutropenia Grade ≥3 Neutropenia
Grade 2 Leukocytopenia Grade ≥3 Leukocytopenia
Grade 2 Thrombocytopenia Grade ≥3 Thrombocytopenia
Grade 2 Anaemiab Grade ≥3 Anaemiab
Studya (N=674) Literature1-3 %%
17.4 3─20 8.6 2─7 3.8 2─10 1.1 -
2.1 7 0.7 -
15.8 15─25 2.3 0─9 9.3 11
1.7 2
3 3─4 0.6 -
0.9 5─8 0.7 1─2 8.5 19─20 1.6 1─2 0.3 -
0.3 -
5.6 7─20 0.4 -
a Selected from this study are all patients with a similar capecitabine schedule to referenced locally advanced rectal patients from literature (825 mg/m2 twice daily, for 5 weeks with or without weekends);
b Data of 266 patients;
c Data of 172 patients.
Abbreviations: HFS: hand-foot syndrome.
208